P Iozzo, K Hallsten, V Oikonen, KA Virtanen, R … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—Fasting plasma glucose levels were significantly decreased after either rosiglitazone
(−0.9 ± 0.5 mmol/l) or metformin treatment (−1.1 ± 0.5 mmol/l) in comparison with placebo; only
metformin was associated with weight loss (P < 0.02 vs. placebo). When controlling for ... Cited by 36 - Related articles - BL Direct - All 5 versions
KA Virtanen, K Hällsten, R Parkkola, T Janatuinen, F … - Diabetes, 2003 - Am Diabetes Assoc We evaluated the effects of rosiglitazone (4 mg bid) and metformin (1 g bid) monotherapy for
26 weeks on adipose tissue insulin-stimulated glucose uptake in patients (n = 41) with type 2
diabetes. Before and after the treatment, glucose uptake was measured using 2-[ 18 ... Cited by 112 - Related articles - BL Direct - All 4 versions
[CITATION] The PPAR [gamma] Agonist, Rosiglitazone, Reverses Hyperinsulinemia and …
- ►diabetesjournals.org K Hällsten, KA Virtanen, F Lönnqvist, H Sipilä, A … - Diabetes, 2002 - Am Diabetes Assoc Rosiglitazone, a thiazolidinedione, enhances peripheral insulin sensitivity in patients with type
2 diabetes. Because the synergic action of insulin and exercise has been shown to be decreased
in insulin resistance, the aim of this study was to compare the effects of rosiglitazone and ... Cited by 98 - Related articles - BL Direct - All 6 versions
